Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 08/05/2008) - In this randomized trial, patients with unresectable or metastatic GIST will receive imatinib therapy with or without the addition of bevacizumab. Researchers hope that the combination of imatinib and bevacizumab will help extend progression-free survival.
Treating Relapsed or Refractory B-cell Lymphomas
(Posted: 07/22/2008) - Scientists are studying the drug flavopiridol in this early phase clinical trial to see if it can be effective in treating diffuse large B-cell lymphoma and mantle cell lymphoma that has relapsed or been resistant to treatment.
New Drugs for Multiple Myeloma Consolidation Therapy
(Posted: 07/08/2008) - In this trial, newly diagnosed multiple myeloma patients who have undergone induction therapy will be treated with consolidation therapy consisting of dexamethasone and the drug bortezomib, and some will also be randomly assigned to receive a third drug called lenalidomide.
Treatment for Advanced Carcinoid Tumors
(Posted: 06/24/2008) - In this trial, patients with advanced nueroendocrine carcinoid tumors that have spread (metastasized) or that cannot be surgically removed (unresectable) will be randomly assigned to receive the drug octreotide acetate along with either bevacizumab or another drug called interferon alfa.
Cilengitide for PSA-Only Progressive Prostate Cancer
(Posted: 03/27/2007, Updated: 06/17/2008) - In this trial, men with prostate cancer that is progressing, as indicated by a rising PSA level, despite antiandrogen therapy will be treated with a drug called cilengitide, which blocks receptor proteins that help prostate cancer grow and spread.